JP2001526241A - Ｈｉｖ感染に対する感受性を低下させるための方法 - Google Patents

Ｈｉｖ感染に対する感受性を低下させるための方法

Info

Publication number
JP2001526241A
JP2001526241A JP2000525129A JP2000525129A JP2001526241A JP 2001526241 A JP2001526241 A JP 2001526241A JP 2000525129 A JP2000525129 A JP 2000525129A JP 2000525129 A JP2000525129 A JP 2000525129A JP 2001526241 A JP2001526241 A JP 2001526241A
Authority
JP
Japan
Prior art keywords
cells
cd40l
hiv
binding
monocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000525129A
Other languages
English (en)
Japanese (ja)
Inventor
トーマス，イレイン・ケイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of JP2001526241A publication Critical patent/JP2001526241A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000525129A 1997-12-19 1998-12-18 Ｈｉｖ感染に対する感受性を低下させるための方法 Pending JP2001526241A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6835597P 1997-12-19 1997-12-19
US60/068,355 1997-12-19
US9847498P 1998-08-31 1998-08-31
US60/098,474 1998-08-31
PCT/US1998/027005 WO1999032138A1 (en) 1997-12-19 1998-12-18 Method for reducing susceptibility to hiv infection

Publications (1)

Publication Number Publication Date
JP2001526241A true JP2001526241A (ja) 2001-12-18

Family

ID=26748884

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000525129A Pending JP2001526241A (ja) 1997-12-19 1998-12-18 Ｈｉｖ感染に対する感受性を低下させるための方法

Country Status (6)

Country Link
EP (1) EP1059932A1 (de)
JP (1) JP2001526241A (de)
AU (1) AU2004199A (de)
CA (1) CA2313805A1 (de)
IL (1) IL136731A0 (de)
WO (1) WO1999032138A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006333866A (ja) 2005-06-02 2006-12-14 Eisho Ryu 自家幹細胞とその用途
JP2007516696A (ja) * 2003-06-13 2007-06-28 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア ＩｇＥシグナルペプチドおよび／またはＩＬ−１５をコードする核酸配列およびそれらを含んでなる組成物およびその使用法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
AU2002232447A1 (en) * 2000-11-02 2002-05-15 Immunex Corporation Method of enhancing lymphocyte-mediated immune responses
US7175838B2 (en) * 2001-08-23 2007-02-13 The United States Of America Represented By The Department Of Health And Human Services Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US8604178B2 (en) 2006-09-18 2013-12-10 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses
CN102037135A (zh) 2007-10-30 2011-04-27 阿肯色大学评议会 增强对有鞭毛的细菌的免疫反应的组合物和方法
DK2214701T3 (en) 2007-11-01 2016-12-12 Univ Arkansas CONFIGURATIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSES TO Eimeria
DK2525817T3 (en) 2010-01-21 2017-10-02 Univ Arkansas Vaccine vectors and methods for enhancing immune responses
JP5746333B2 (ja) 2010-06-09 2015-07-08 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー カンピロバクター感染を減少させるワクチン及び方法
PT2956165T (pt) 2013-02-14 2019-11-29 Texas A & M Univ Sys Composições e métodos de potenciação das respostas imunitárias frente a eimeria ou limitação de uma infeção por eimeria
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
EP3452069A4 (de) 2016-05-03 2020-02-12 The Board of Trustees of the University of Arkansas Hefeimpfstoffvektor mit immunstimulierenden und antigenen polypeptiden und verfahren zur verwendung davon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014487A1 (en) * 1993-11-24 1995-06-01 The Australian National University Treatment of viral disease with cd40l peptide
DE69433820T2 (de) * 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
KR19980702490A (ko) * 1995-03-01 1998-07-15 스티븐 엘. 말라스카 면역 반응의 자극 방법

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007516696A (ja) * 2003-06-13 2007-06-28 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア ＩｇＥシグナルペプチドおよび／またはＩＬ−１５をコードする核酸配列およびそれらを含んでなる組成物およびその使用法
JP2012110345A (ja) * 2003-06-13 2012-06-14 Trustees Of The Univ Of Pennsylvania ＩｇＥシグナルペプチドおよび／またはＩＬ−１５をコードする核酸配列およびそれらを含む組成物およびその使用法
JP2006333866A (ja) 2005-06-02 2006-12-14 Eisho Ryu 自家幹細胞とその用途

Also Published As

Publication number Publication date
AU2004199A (en) 1999-07-12
EP1059932A1 (de) 2000-12-20
IL136731A0 (en) 2001-06-14
WO1999032138A1 (en) 1999-07-01
CA2313805A1 (en) 1999-07-01

Similar Documents

Publication Publication Date Title
JP7288405B2 (ja) ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体
WO2019129053A1 (zh) 以抗体Fc区为骨架的融合蛋白二聚体及其应用
US6569997B1 (en) Antibody specific for H4-1BB
AU680102B2 (en) Method of preventing or treating disease characterized by neoplastic cells expressing CD40
JP5312721B2 (ja) Ｃｄ１９特異的再指向免疫細胞
Sharron et al. Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes
WO2021213421A1 (zh) 融合蛋白分子及其制备方法和用途
AU693526B2 (en) Immuno-stimulatory monoclonal antibodies
EP0672143B1 (de) Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
KR20180057723A (ko) 항-cd30 키메라성 항원 수용체
JP2001526241A (ja) Ｈｉｖ感染に対する感受性を低下させるための方法
Levitt et al. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
MXPA05007129A (es) Usos de la citocina de mamifero; reactivos relacionados.
JP3657271B2 (ja) 病原性または日和見感染性生物に感染した哺乳動物の治療のための組成物
CN110305847B (zh) 一种用于治疗肿瘤的基因工程细胞
JP2022023136A (ja) Ｔ細胞の拡張及び活性化の方法
US5670149A (en) Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US20230303705A1 (en) Binders and chimeric antigen receptors specific for interleukin-1 receptor accessory protein
Zambello et al. Role of tumor necrosis factor-alpha and its specific 55-Kd and 75-Kd receptors in patients with lymphoproliferative disease of granular lymphocytes
Zambello et al. IL‐12 is involved in the activation of CD3+ granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes
RU2776890C9 (ru) Клеточная терапия, основанная на улучшенных клетках-естественных киллерах
RU2776890C2 (ru) Клеточная терапия, основанная на улучшенных клетках-естественных киллерах
TW202332771A (zh) 轉基因免疫細胞及其構建方法和應用
Waldmann et al. The interleukin-2 receptor: a target for immunotherapy
Maeda et al. Acquisition of HIV type 1 resistance by beta-chemokine-producing CD4+ T cells

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040803

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050114